Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

19 July 2016 : Original article  

Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience

Yasuhiro OguraABCDEFG, Hisashi ImaiABCD, Hideya KameiB, Tomohide HoriB, Nobuhiko KurataB, Yasuharu OnishiB

DOI: 10.12659/AOT.898604

Ann Transplant 2016; 21:448-455

Abstract

BACKGROUND: Prolonged-release tacrolimus (Tac QD) is widely used in organ transplantation. However, the conversion from twice-daily tacrolimus (Tac BID) to Tac QD in Japan is usually done in stable patients months or years after liver transplantation. The aim of this study was to assess the early conversion of Tac QD during liver transplant hospital stay.

MATERIAL AND METHODS: Eighteen liver transplants (excluding pediatric) were performed during 2014–2015. All cases except 2 early-expired patients were enrolled. Our standard immunosuppression is oral Tac BID and steroid taper, and we add mycophenolate mofetil if indicated. Conversion criteria from Tac BID to Tac QD were: 1) relatively stable liver function with stable trough level by oral Tac BID, and 2) good general condition (no or well-controlled complications). We did not fix the exact conversion date because each patient’s recovery was different. Dose conversion rate from Tac BID to Tac QD was set at 1:1.

RESULTS: The median number of conversion days after liver transplant was 27 days. Sixty-two percent of patients were converted within 4 weeks after liver transplant, and 56% were discharged from the hospital within 2 weeks after conversion. The comparison of the last week of Tac BID and the first week of Tac QD revealed that the mean tacrolimus trough level declined by 30.4%, resulting in the 26.2% tacrolimus dose increase during the first 2 weeks after conversion. Adverse events after conversion were limited, and all patients show normal liver function to date.

CONCLUSIONS: Early Tac QD conversion is safe and feasible, but its long-term effects need further investigation.

Keywords: Immunosuppression, Liver Transplantation, Tacrolimus

Add Comment 0 Comments

In Press

Original article  

Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantati...

Ann Transplant In Press; DOI: 10.12659/AOT.947186  

Case report  

Pulmonary Embolism Following Living Donor Hepatectomy: A Report of 4 Cases and Literature Review

Ann Transplant In Press; DOI: 10.12659/AOT.946752  

Most Viewed Current Articles

03 Jan 2023 : Original article   6,513

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...

DOI :10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

15 Aug 2023 : Review article   6,136

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

DOI :10.12659/AOT.939750

Ann Transplant 2023; 28:e939750

16 May 2023 : Original article   6,130

Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...

DOI :10.12659/AOT.939258

Ann Transplant 2023; 28:e939258

17 Jan 2023 : Original article   5,257

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation i...

DOI :10.12659/AOT.938595

Ann Transplant 2023; 28:e938595

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358